Additionally, fucoxanthin exhibits broad-spectrum anticancer activity by suppressing cyclin and CDK expression in gastric and bladder cancers and modulating JAK/STAT pathways in dose dependent manner (50–75 μM) (Wang et al. 2014; Yu et al. 2011). The gene discussed is SOAT1; the disease is urinary bladder cancer.